Skip to main content
Press Enter
BASF offers the world's largest portfolio of chemical raw materials for the pharmaceutical industry, ensuring the needs of our partners are always met. Every step of biopharmaceutical manufacturing requires high-quality raw materials delivered through a transparent, sustainable supply chain. BASF Biopharma Ingredients is committed to meeting your requirements for every ingredient we supply to the biologics industry. At BASF, we create excipients that are safe, effective, and convenient for your customers. Whether you’re developing orally disintegrating formulations that require taste-masking or modified release tablets, BASF has ingredients to deliver the precision you need, every time. At BASF, we offer a comprehensive range of cutting-edge solubilization polymers, and have an unparalleled understanding of the corresponding process technologies. BASF offers an unparalleled portfolio of excipients for topical formulations, enabling you with the tools to overcome formulation challenges. With products based on over 150 years of industry experience, BASF is committed to maintaining the highest level of quality across the product spectrum. BASF offers a broad portfolio of chemistries designed to simplify the product development process. Coating polymers are suitable for a variety of oral formulation challenges. As multifunctional excipients, ethoxylated solubilizers are known for their utility across a large range of dosage form classes. BASF's pharma grade lipid-based excipients are manufactured in GMP-compliant facilities with high quality and reliability in mind. BASF's portfolio of poloxamers are renown for their best-in-class quality. Consisting of a broad portfolio of polyethylene glycols (PEGs), BASF's portfolio of ethoxylated polymer-solubilizers is known for its versatility across a myriad of dosage forms. BASF offers a broad portfolio of functional excipients including our pharmaceutical grade polysorbate and sorbitan esters. Povidones, copovidones, and crospovidones are versatile materials that serve as the foundation of oral solid dosage forms. BASF's portfolio of solvents and co-solvents are suitable for a wide range of applications and processing methodologies. BASF offers a broad portfolio of brand families that are suitable for oral, topical, parenteral, and biologic applications. Coprocessed excipients are combination, all-in-one solutions. Kollicoat® coating polymers are suitable for a variety of oral formulation challenges. Kollicream® pharma grade solvents and emollients are manufactured in GMP-compliant facilities with high quality and reliability in mind. Kollidon® povidones, copovidones, and crospovidones are versatile materials that are most commonly used for solid oral dosage forms. Kolliphor® solubilizers, emulsifiers, co-emulsifiers, and surfactants enable the development of safe and effective formulations. Kollipro™ processing aids offer high-quality fit-for-purpose solutions that optimize manufacturing efficiency. Kollisolv® solubilizers and solvents are suitable for a wide range of applications and processing methodologies. Kolliwax® structuring agents, moisture barriers, and lubricants enable the formulation of various dosage forms. Novata® hard fats are structuring agents and matrix builders. Soluplus® is a novel solubilizer, crystallization inhibitor, and a matrix forming polymer. Explore this collection of resources to learn more about our innovative research and pharma solutions.

DDF Berlin 2024: Global Drug Delivery & Formulation summit

The Global Drug Delivery and Formulation Summit is a leading event for professionals in the pharmaceutical industry specializing in drug delivery, formulation, and device development. The summit features over 100 scientific presentations, more than 90 industry experts as speakers, and includes four content streams spread over three days. The comprehensive agenda covers four key content streams: Small Molecules, Biologics, Technology & Innovation, and Device Development.

Poloxamer 188 variant for the formulation of biologics

Surfactants are used in the biopharmaceutical industry to stabilize antibodies in biologic formulations. In our research, a hydrophobic variant of Poloxamer 188 has shown promise in the formulation of biologics, particularly when used with primary packaging containing PDMS. We will share, that this formulation has been found to result in fewer visible particles of Protein-PDMS after prolonged storage compared to formulations with less hydrophobic P188. Additionally, the hydrophobic P188 has demonstrated a positive impact on antibody aggregation, with fewer larger aggregates detected after stress induction. These findings suggest that the use of hydrophobic P188 can improve the stability and quality of biologic formulations.

Join the presentation "Poloxamer 188 variant for the formulation of biologics" of our expert Nadine Löw on Thursday, May 23, 9:40am!

Speaker

Nadine Löw

Nadine Löw
Development Pharma Solutions, 
BASF Pharma Solutions

LinkedIn Profile